Association of anaemia in primary care patients with chronic kidney disease: Cross sectional study of quality improvement in chronic kidney disease (QICKD) trial data

BMC Nephrology

Volumn 14, Issue 1, 2013, Pages

  Dmitrieva, Olga ^a   De Lusignan, Simon ^a   Macdougall, Iain C ^b   Gallagher, Hugh ^c   Tomson, Charles ^d   Harris, Kevin ^e   Desombre, Terry ^a   Goldsmith, David ^f  

^a UNIVERSITY OF SURREY   (United Kingdom)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

^c ST HELIER HOSPITAL   (United Kingdom)

^d SOUTHMEAD HOSPITAL   (United Kingdom)

^e UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

^f GUY S HOSPITAL   (United Kingdom)

Author keywords

Aspirin; Chronic, Anaemia; Data collection; Erythropoietin; Family practice; Iron deficiency; Medical records systems, Computerized; Renal insufficiency chronic

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; FERRITIN; FERROUS FUMARATE; FERROUS SULFATE; HEMOGLOBIN; IRON; NONSTEROID ANTIINFLAMMATORY AGENT; WARFARIN;

ADULT; AGED; ANEMIA; CHRONIC KIDNEY DISEASE; COMORBIDITY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; GASTROINTESTINAL HEMORRHAGE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEAN CORPUSCULAR VOLUME; MICROCYTIC ANEMIA; NORMOCHROMIC NORMOCYTIC ANEMIA; OBSERVATIONAL STUDY; PRESCRIPTION; PRIMARY MEDICAL CARE; REVIEW; TOTAL QUALITY MANAGEMENT;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PRIMARY HEALTH CARE; QUALITY IMPROVEMENT; RENAL INSUFFICIENCY, CHRONIC;

EID: 84872762492     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-14-24     Document Type: Review

References (59)

1. Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. Horwich TB, Fonarow GC, Hamilton MA, MacLellan WR, Borenstein J, J Am Coll Cardiol 2002 39 11 1780 1786 10.1016/S0735-1097(02) 01854-5 12039491
2. Anemia predicts mortality in severe heart failure: the prospective randomized amlodipine survival evaluation (PRAISE). Mozaffarian D, Nye R, Levy WC, J Am Coll Cardiol 2003 41 11 1933 1939 10.1016/S0735-1097(03)00425-X 12798560
3. Managing a fateful alliance: anaemia and cardiovascular outcomes. Eckardt KU, Nephrol Dial Transplant 2005 20 Suppl 6 &22i16 20 15958821
4. Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988-1994). Astor BC, Muntner P, Levin A, Eustace JA, Coresh J, Arch Intern Med 2002 162 12 1401 1408 10.1001/archinte.162.12. 1401 12076240
5. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS, Am J Kidney Dis 2003 41 1 1 12 12500213
6. PRE-dialysis survey on anaemia management. Valderrabano F, Horl WH, Macdougall IC, Rossert J, Rutkowski B, Wauters JP, Nephrol Dial Transplant 2003 18 1 89 100 10.1093/ndt/18.1.89 12480965
7. Unreferred chronic kidney disease: a longitudinal study. John R, Webb M, Young A, Stevens PE, Am J Kidney Dis 2004 43 5 825 835 10.1053/j.ajkd.2003.12. 046 15112173
8. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Canadian Erythropoietin Study Group. Canadian Erythropoietin Study Group, BMJ 1990 300 6724 573 578 2108751
9. Health-related quality of life and hemoglobin levels in chronic kidney disease patients. Finkelstein FO, Story K, Firanek C, Mendelssohn D, Barre P, Takano T, Soroka S, Mujais S, Clin J Am Soc Nephrol 2009 4 1 33 38 10.2215/CJN.00630208 18987300
10. Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors. Harnett JD, Foley RN, Kent GM, Barre PE, Murray D, Parfrey PS, Kidney Int 1995 47 3 884 890 10.1038/ki.1995.132 7752588
11. Anemia as a predictor of cardiovascular events in patients with elevated serum creatinine. Walker AM, Schneider G, Yeaw J, Nordstrom B, Robbins S, Pettitt D, J Am Soc Nephrol 2006 17 8 2293 2298 10.1681/ASN.2005020183 16837634
12. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Levin A, Thompson CR, Ethier J, Carlisle EJ, Tobe S, Mendelssohn D, Burgess E, Jindal K, Barrett B, Singer J, et al. Am J Kidney Dis 1999 34 1 125 134 10.1016/S0272-6386(99)70118-6 10401026
13. Higher prevalence of anemia with diabetes mellitus in moderate kidney insufficiency: The Kidney Early Evaluation Program. El-Achkar TM, Ohmit SE, McCullough PA, Crook ED, Brown WW, Grimm R, Bakris GL, Keane WF, Flack JM, Kidney Int 2005 67 4 1483 1488 10.1111/j.1523-1755.2005.00226.x 15780101
14. Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction. Ishani A, Weinhandl E, Zhao Z, Gilbertson DT, Collins AJ, Yusuf S, Herzog CA, J Am Coll Cardiol 2005 45 3 391 399 10.1016/j.jacc.2004.10.038 15680718
15. An educational intervention, involving feedback of routinely collected computer data, to improve cardiovascular disease management in UK primary care. de Lusignan S, Methods Inf Med 2007 46 1 57 62 17224982
16. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease. Maddux FW, Shetty S, del Aguila MA, Nelson MA, Murray BM, Ann Pharmacother 2007 41 11 1761 1769 10.1345/aph.1K194 17895328
17. The impact of renal insufficiency and anaemia on survival in patients with cardiovascular disease: a cohort study. Anderson J, Glynn LG, Newell J, Iglesias AA, Reddan D, Murphy AW, BMC Cardiovasc Disord 2009 9 51 10.1186/1471-2261-9-51 19909540
18. Erythropoietin therapy and left ventricular mass index in CKD and ESRD patients: a meta-analysis. Parfrey PS, Lauve M, Latremouille-Viau D, Lefebvre P, Clin J Am Soc Nephrol 2009 4 4 755 762 10.2215/CJN.02730608 19339417
19. Changes in left ventricular size, wall thickness, and function in anemic patients treated with recombinant human erythropoietin. Goldberg N, Lundin AP, Delano B, Friedman EA, Stein RA, Am Heart J 1992 124 2 424 427 10.1016/0002-8703(92)90608-X 1386184
20. Postdialysis outcomes associated with consistent anemia treatment in predialysis patients with chronic kidney disease. Wish JB, Nassar GM, Schulman K, del Aguila M, Provenzano R, Clin Nephrol 2008 69 4 251 259 18397699
21. Hemoglobin targets and blood transfusions in hemodialysis patients without symptomatic cardiac disease receiving erythropoietin therapy. Foley RN, Curtis BM, Parfrey PS, Clin J Am Soc Nephrol 2008 3 6 1669 1675 10.2215/CJN.02100508 18922988
22. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Kuriyama S, Tomonari H, Yoshida H, Hashimoto T, Kawaguchi Y, Sakai O, Nephron 1997 77 2 176 185 10.1159/000190270 9346384
23. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. Silverberg DS, Wexler D, Blum M, Keren G, Sheps D, Leibovitch E, Brosh D, Laniado S, Schwartz D, Yachnin T, et al. J Am Coll Cardiol 2000 35 7 1737 1744 10.1016/S0735-1097(00)00613-6 10841219
24. Anaemia Management in Chronic Kidney Disease. Rapid Update 2011. Clinical Guideline. Methods, evidence and recommendations. National Institute for Health and Clinical Excellence, CG114. [ http://www.nice.org.uk/nicemedia/live/13329/ 52851/52851.pdf ]
25. Clinical practice guidelines. Anaemia in CKD. [ http://www.renal.org/ Clinical/GuidelinesSection/AnaemiaInCKD.aspx ]
26. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Mancini DM, Katz SD, Lang CC, LaManca J, Hudaihed A, Androne AS, Circulation 2003 107 2 294 299 10.1161/01.CIR. 0000044914.42696.6A 12538431
27. Erythropoiesis stimulating agents in heart failure patients with anemia: a meta-analysis. Tehrani F, Dhesi P, Daneshvar D, Phan A, Rafique A, Siegel RJ, Cercek B, Cardiovasc Drugs Ther 2009 23 6 511 518 10.1007/s10557-009-6203-6 19862609
28. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. Ghali JK, Anand IS, Abraham WT, Fonarow GC, Greenberg B, Krum H, Massie BM, Wasserman SM, Trotman ML, Sun Y, et al. Circulation 2008 117 4 526 535 10.1161/CIRCULATIONAHA.107.698514 18195176
29. Impact of erythropoiesis-stimulating agents on morbidity and mortality in patients with heart failure: an updated, post-TREAT meta-analysis. Desai A, Lewis E, Solomon S, McMurray JJ, Pfeffer M, Eur J Heart Fail 2010 12 9 936 942 10.1093/eurjhf/hfq094 20525985
30. The controversy surrounding hemoglobin and erythropoiesis-stimulating agents: what should we do now? Singh AK, Am J Kidney Dis 2008 52 6 Suppl 5 13 19010260
31. FDA modifies dosing recommendations for Erythropoiesis-Stimulating Agents. [ http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm260670. htm ]
32. The QICKD study protocol: a cluster randomised trial to compare quality improvement interventions to lower systolic BP in chronic kidney disease (CKD) in primary care. de Lusignan S, Gallagher H, Chan T, Thomas N, van Vlymen J, Nation M, Jain N, Tahir A, du Bois E, Crinson I, et al. Implement Sci 2009 4 39 10.1186/1748-5908-4-39 19602233
33. Using audit-based education to lower systolic blood pressure in chronic kidney disease (CKD): results of the quality improvement in CKD (QICKD) trial [ISRCTN: 56023731]. de Lusignan S, Gallagher H, Jones S, Chan T, van Vlymen J, Tahir A, Thomas N, Jain N, Dmitrieva O, Rafi I, et al. Accepted for Publication Kidney International, 13th January 2013, Ref: KI-06-12-0863.R3
34. Ensuring the quality of aggregated general practice data: lessons from the primary care data Quality Programme (PCDQ). van Vlymen J, de Lusignan S, Hague N, Chan T, Dzregah B, Stud Health Technol Inform 2005 116 1010 1015 16160391
35. A system of metadata to control the process of query, aggregating, cleaning and analysing large datasets of primary care data. van Vlymen J, de Lusignan S, Inform Prim Care 2005 13 4 281 291 16510025
36. Measure of multiple deprivation at small area level made up of seven domains. Index of Multiple Deprivation (IMD), [ http://data.gov.uk/dataset/imd- 2004 ]
37. Creatinine fluctuation has a greater effect than the formula to estimate glomerular filtration rate on the prevalence of chronic kidney disease. de Lusignan S, Tomson C, Harris K, van Vlymen J, Gallagher H, Nephron Clin Pract 2011 117 3 213 224 10.1159/000320341 20805694
38. Chronic kidney disease. National clinical guideline for early identification and management in adults in primary and secondary care (Clinical Guideline 73). National Institute for Health and Clinical Excellence (NICE), [ http://www.nice.org.uk/nicemedia/live/12069/42117/42117.pdf ]
39. Creatinine fluctuation has a greater effect than the formula to estimate glomerular filtration rate on the prevalence of chronic kidney disease. de Lusignan S, Tomson C, Harris K, van Vlymen J, Gallagher H, Nephron Clin Pract 2010 117 3 213 c224 20805694
40. Erythrocyte volume distribution in normal and abnormal subjects. Bessman JD, Johnson RK, Blood 1975 46 3 369 379 1148395
41. Practical approach to the diagnosis and treatment of anemia associated with CKD in elderly. Agarwal AK, J Am Med Dir Assoc 2006 7 9 Suppl 7 S12 quiz S17-21 17098634
42. Update on clinical practice recommendations and new therapeutic modalities for treating anemia in patients with chronic kidney disease. Grabe DW, Am J Health Syst Pharm 2007 64 13 Suppl 8 8 14 quiz S23-15 17909275
43. Bone marrow iron, iron indices, and the response to intravenous iron in patients with non-dialysis-dependent CKD. Stancu S, Stanciu A, Zugravu A, Barsan L, Dumitru D, Lipan M, Mircescu G, Am J Kidney Dis 2010 55 4 639 647 10.1053/j.ajkd.2009.10.043 20079959
44. Best practice in primary care pathology: review 3. Smellie WS, Forth J, Bareford D, Twomey P, Galloway MJ, Logan EC, Smart SR, Reynolds TM, Waine C, J Clin Pathol 2006 59 8 781 789 10.1136/jcp.200X.033944 16873560
45. Guidelines for the management of iron deficiency anaemia. Goddard AF, James MW, McIntyre AS, Scott BB, Gut 2011
46. Age-specific associations of reduced estimated glomerular filtration rate with concurrent chronic kidney disease complications. Bowling CB, Inker LA, Gutierrez OM, Allman RM, Warnock DG, McClellan W, Muntner P, Clin J Am Soc Nephrol 2011 6 12 2822 2828 10.2215/CJN.06770711 22034504
47. A system for solution-orientated reporting of errors associated with the extraction of routinely collected clinical data for research and quality improvement. Michalakidis G, Kumarapeli P, Ring A, van Vlymen J, Krause P, de Lusignan S, Stud Health Technol Inform 2010 160 Pt 1 724 728 20841781
48. Identifying patients with chronic kidney disease from general practice computer records. de Lusignan S, Chan T, Stevens P, O'Donoghue D, Hague N, Dzregah B, Van Vlymen J, Walker M, Hilton S, Fam Pract 2005 22 3 234 241 10.1093/fampra/cmi026 15814579
49. Comparing intervention to lower systolic blood pressure in chronic kidney disease (CKD): a Cluster Randomised Trial (CRT). ISRCTN56023731. [ http://www.controlled-trials.com/ISRCTN56023731/56023731 ]
50. Clinical Practice Guideline for anaemia in chronic disease. Kidney Disease Improving Global Outcomes (KDIGO), Kidney International 2012 2 282 10.1038/kisup.2012.40
51. Prevalence and associations of anemia of CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004. McFarlane SI, Chen SC, Whaley-Connell AT, Sowers JR, Vassalotti JA, Salifu MO, Li S, Wang C, Bakris G, McCullough PA, Kidney Early Evaluation Program Investigators, et al. Am J Kidney Dis 2008 51 4 Suppl 2 46 55 10.1053/j.ajkd.2007.12.019 18359408
52. Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta-analysis. Rozen-Zvi B, Gafter-Gvili A, Paul M, Leibovici L, Shpilberg O, Gafter U, Am J Kidney Dis 2008 52 5 897 906 10.1053/j.ajkd.2008.05.033 18845368
53. Relationship between glomerular filtration rate and the prevalence of metabolic abnormalities: results from the Third National Health and Nutrition Examination Survey (NHANES III). Clase CM, Kiberd BA, Garg AX, Nephron Clin Pract 2007 105 4 178 184 10.1159/000100489 17347576
54. High dose enalapril impairs the response to erythropoietin treatment in haemodialysis patients. Albitar S, Genin R, Fen-Chong M, Serveaux MO, Bourgeon B, Nephrol Dial Transplant 1998 13 5 1206 1210 10.1093/ndt/13.5.1206 9623555
55. The use of routinely collected computer data for research in primary care: opportunities and challenges. de Lusignan S, van Weel C, Fam Pract 2006 23 2 253 263 16368704
56. CPR 1.1. Identifying patients and initiating evaluation II. Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease in adults. Am J Kidney Dis 2006 47 5 Suppl 3 16 85 16678661
57. Iron deficiency anaemia. Assessment, prevention and control. A guide for programme managers. [ http://www.who.int/nutrition/publications/micronutrients/ anaemia-iron-deficiency/WHO-NHD-01.3/en/ ]
58. Mikhail A, Shrivastava R, Richardson D, Clinical practice guidelines, Anaemia of CKD UK Renal Association 5 2009 2012 URL: http://www.renal.org/ Libraries/Guidelines/Anaemia-in-CKD-Draft-Version-15-February-2010.sflb.ashx
59. Assessing iron status: beyond serum ferritin and transferrin saturation. Wish JB, Clin J Am Soc Nephrol 2006 1 Suppl 1 4 8 17699374